Abstracts tagged "activity score and polymyalgia rheumatica"

Abstract Number: 882 • 2016 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Activity Score without C-Reactive Protein
Valerie Devauchelle^1,2, Lea Saraux³, Jean-Marie Berthelot⁴, Divi Cornec⁵, Thierry Marhadour⁶, Sandrine Jousse-Joulin⁷, Michel De Bandt⁸, Maelenn Gouillou⁹ and Alain Saraux¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, Lab Ex, INSERM, IGO,UBO and CHU de la Cavale Blanche,, Brest, France, ²Service de Rhumatologie, Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Department of rheumatology, Brest Occidentale University, Brest, France, ⁶Rheumatology, CHU La Cavale Blanche, Brest, France, ⁷Rheumatology, CHu La cavle Blanche, Brest, France, ⁸CHU Fort de France, Fort de France, France, ⁹Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ¹⁰Department of rheumatology and unit of immunology (EA 2216), CHU Brest et Université Bretagne Occidentale, Brest, France
Background/Purpose: Disease activity of polymyalgia rheumatica (PMR) (1, 2) may be evaluated using the PMR activity score (PMR-AS). For patients without measure of CRP, or patients…
Abstract Number: 2382 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica
E.M. McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Accurate determination of disease activity in polymyalgia rheumatica(PMR) is challenging due to the subjective nature of symptoms and concurrent musculoskeletal complaints in an elderly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].